1-4 of 4
Clarence Eng, MPH
Close
Sort by
Journal Articles

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Mark D. Minden, MD PhD, Wendy Stock, MD, Howland Crosswell, MD, Robert D Siegel, MD, Patrick Chun, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Dan Douer, MD
Journal: Blood
Blood (2015) 126 (23): 4866.
https://doi.org/10.1182/blood.V126.23.4866.4866
Published: 2015
Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Julie Di Paolo, PhD, Clarence Eng, MPH, Jing Hu, PhD, Jing He, Anita Reddy, PhD, Christopher A. Yasenchak, MD
Journal: Blood
Blood (2015) 126 (23): 4152.
https://doi.org/10.1182/blood.V126.23.4152.4152
Published: 2015
Journal Articles

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Jeff P. Sharman, MD, Andrei R. Shustov, MD, Mitchell R. Smith, MD PhD, Thomas E. Boyd, MD, Christopher Hagenstad, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Jing Hu, PhD, Anita Reddy, PhD, Siddhartha Mitra, MDPhD, Christopher A. Yasenchak, MD, Farrukh T. Awan, MD MS
Journal: Blood
Blood (2015) 126 (23): 1744.
https://doi.org/10.1182/blood.V126.23.1744.1744
Published: 2015
Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Clarence Eng, MPH, Jing He, Jing Hu, PhD, Christopher A. Yasenchak, MD
Journal: Blood
Blood (2015) 126 (23): 1545.
https://doi.org/10.1182/blood.V126.23.1545.1545
Published: 2015